Aalya Hamouda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aalya Hamouda has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Abdulla Alameeri
Division of Urology McGill University Montreal QC Canada
1 shared publication - Adel Arezki
Division of Urology, McGill University, Montreal, Canada
1 shared publication - Alexander P. Glaser
Division of Urology NorthShore University Health System Evanston IL USA
1 shared publication - Anouk Leathead
Faculty of Medicine University of Montreal Montreal QC Canada
1 shared publication Brian Helfand
Division of Urology NorthShore University Health System Evanston IL USA
1 shared publication- Claudia Covarrubias
Lady Davis Research Institute, McGill University, Montreal, Quebec, Canada
1 shared publication
Latest Publications
- Open Access
- 7 October 2026
- Published by Wiley in BJU International
- Vol. 138 (6) , 1171-1179
Aquablation as salvage therapy for benign prostatic hyperplasia: an international multicentre study
Objective: Our objective was to evaluate the safety and effectiveness of Aquablation® as a salvage therapy in patients who underwent prior intervention for benign prostatic hyperplasia (BPH). Materials and Methods: We retrospectively analysed 1887 consecutive men from the International Collaborative Aquablation Research Urology Society database between 2018 and 2024 who underwent Aquablation at one of four international centres. The cohort was divided into two groups based on the presence or absence of previous BPH intervention. Baseline characteristics, clinical and functional outcomes, and complication rates were compared between the two groups using analysis of variance and Kruskal–Wallis tests. Finally, exploratory sub‐analyses were performed in the salvage therapy group based on the type of prior BPH intervention. Results: Among the study population of 1887 men, 109 (5.8%) patients had undergone prior BPH intervention, and the remaining 1778 (94.2%) patients served as a control cohort. Prostate volumes were similar between both groups (82.3 vs 78.0 mL; P = 0.18). There were no significant differences in perioperative complications, 30‐day readmission rates, surgical retreatment rates, or sexual function outcome scores (all P > 0.05). There were also similar improvements in maximum urinary flow rates, post‐void residuals, International Prostate Symptom Scores, and quality of life scores (all P > 0.05). When comparing outcomes based on the type of prior BPH intervention, there were no differences in terms of operative time, prostate volumes, presence of median lobe, or complication rates. Conclusion: We observed no statistically significant differences in safety or effectiveness for Aquablation as a salvage therapy for recurrent lower urinary tract symptoms after BPH intervention. Aquablation should be offered to men for whom prior procedures have failed and who want to preserve continence and sexual function.
- 7 October 2026
- Published by Wiley in BJU International
- Vol. 138 (6) , 1171-1179
Open AccessAquablation as salvage therapy for benign prostatic hyperplasia: an international multicentre study
Objective: Our objective was to evaluate the safety and effectiveness of Aquablation® as a salvage therapy in patients who underwent prior intervention for benign prostatic hyperplasia (BPH). Materials and Methods: We retrospectively analysed 1887 consecutive men from the International Collaborative Aquablation Research Urology Society database between 2018 and 2024 who underwent Aquablation at one of four international centres. The cohort was divided into two groups based on the presence or absence of previous BPH intervention. Baseline characteristics, clinical and functional outcomes, and complication rates were compared between the two groups using analysis of variance and Kruskal–Wallis tests. Finally, exploratory sub‐analyses were performed in the salvage therapy group based on the type of prior BPH intervention. Results: Among the study population of 1887 men, 109 (5.8%) patients had undergone prior BPH intervention, and the remaining 1778 (94.2%) patients served as a control cohort. Prostate volumes were similar between both groups (82.3 vs 78.0 mL; P = 0.18). There were no significant differences in perioperative complications, 30‐day readmission rates, surgical retreatment rates, or sexual function outcome scores (all P > 0.05). There were also similar improvements in maximum urinary flow rates, post‐void residuals, International Prostate Symptom Scores, and quality of life scores (all P > 0.05). When comparing outcomes based on the type of prior BPH intervention, there were no differences in terms of operative time, prostate volumes, presence of median lobe, or complication rates. Conclusion: We observed no statistically significant differences in safety or effectiveness for Aquablation as a salvage therapy for recurrent lower urinary tract symptoms after BPH intervention. Aquablation should be offered to men for whom prior procedures have failed and who want to preserve continence and sexual function.
- 6 November 2025
- Published by Wiley in Neurourology and Urodynamics
- Vol. 45 (8) , 1473-1475
Advancing Personalized Care for Neurogenic Bladder What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD: Pro Anticholinergic
Aims: To discuss the benefits and considerations of anticholinergic therapy as first‐line treatment for bladder storage symptoms in patients with neurogenic lower urinary tract dysfunction (NLUTD), integrating evidence‐based data and clinical experience. Methods: A narrative review of international guideline recommendations, available clinical evidence, and professional experience was undertaken to evaluate the role of anticholinergics in managing disorders of bladder storage, such as neurogenic detrusor overactivity (NDO) and intrinsic sphincter dyssynergia (NISD), in patients with NLUTD. Results: Evidence from published studies and guideline statements supports anticholinergics as effective agents for improving lower urinary tract symptoms (LUTS), detrusor overactivity (DO), and overall bladder function in patients with NLUTD. Their use has also been associated with prevention of secondary urinary complications. Conclusions: Anticholinergics remain recommended first‐line therapy for bladder storage dysfunction in NLUTD. Clinical use should be guided by individual patient characteristics, balancing efficacy in symptom control with potential side effects and long‐term safety considerations.
- 6 November 2025
- Published by Wiley in Neurourology and Urodynamics
- Vol. 45 (8) , 1473-1475
Advancing Personalized Care for Neurogenic Bladder What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD: Pro Anticholinergic
Aims: To discuss the benefits and considerations of anticholinergic therapy as first‐line treatment for bladder storage symptoms in patients with neurogenic lower urinary tract dysfunction (NLUTD), integrating evidence‐based data and clinical experience. Methods: A narrative review of international guideline recommendations, available clinical evidence, and professional experience was undertaken to evaluate the role of anticholinergics in managing disorders of bladder storage, such as neurogenic detrusor overactivity (NDO) and intrinsic sphincter dyssynergia (NISD), in patients with NLUTD. Results: Evidence from published studies and guideline statements supports anticholinergics as effective agents for improving lower urinary tract symptoms (LUTS), detrusor overactivity (DO), and overall bladder function in patients with NLUTD. Their use has also been associated with prevention of secondary urinary complications. Conclusions: Anticholinergics remain recommended first‐line therapy for bladder storage dysfunction in NLUTD. Clinical use should be guided by individual patient characteristics, balancing efficacy in symptom control with potential side effects and long‐term safety considerations.